We are developing an innovative and transformative approach to quickly delivering targeted Therapeutic Hypothermia

Our technology enables flexibility in methods of delivery to enable therapy that fits within current treatment regimens.


Therapeutic Hypothermia is neuro-protective

Therapeutic Hypothermia (TH) is currently used for neuro-protection when treating cardiac arrest, stroke, and traumatic brain injury. TH is also used to prevent ischemic injury during thoracic/abdominal aortic aneurism (TAA and AAA) repair procedures.

Our technology offers a more cost effective solution that provides flexibility to physicians

Our patented technology overcomes barriers preventing long sought use of Therapeutic Hypothermia

  • Seamless integration with current treatment regimens
  • Utilizes implants currently used in surgical treatment
  • Safely delivers targeted, localized hypothermia
  • Precise temperature control perioperatively and postoperatively
  • Compatible with Electrophysiology Monitoring

Our Preclinical Trials have successfully demonstrated:

  • Clinical use of our system and therapy
  • Safety of localized therapeutic hypothermia
  • Efficacy of localized therapeutic hypothermia for neuroprotection
  • Electrophysiology Monitoring compatibility throughout surgical procedure via SSEP and MEP

Leadership Team

Michael Fehlings, MD, PHD
Chief Medical Officer

John Sullivan
President / CEO

Mike Drnek
Director of R&D

Dan Farley
Board Chairman